TY - JOUR
T1 - Secondary hormonal manipulations in prostate cancer
AU - Ryan, Charles J.
AU - Small, Eric J.
PY - 2005/5
Y1 - 2005/5
N2 - Virtually all patients treated with androgen deprivation eventually develop progressive clinical or biochemical disease despite this therapy. Despite low levels of androgen, the androgen receptor remains active, making secondary hormonal therapies a reasonable clinical approach. Considerations for such patients include antiandrogen withdrawal, sequential use of antiandrogens, adrenal cortex inhibitors, and estrogenic compounds. Collectively, the modest activity of these therapies challenges the notion that advancing prostate cancer will uniformly become "hormone refractory."
AB - Virtually all patients treated with androgen deprivation eventually develop progressive clinical or biochemical disease despite this therapy. Despite low levels of androgen, the androgen receptor remains active, making secondary hormonal therapies a reasonable clinical approach. Considerations for such patients include antiandrogen withdrawal, sequential use of antiandrogens, adrenal cortex inhibitors, and estrogenic compounds. Collectively, the modest activity of these therapies challenges the notion that advancing prostate cancer will uniformly become "hormone refractory."
UR - http://www.scopus.com/inward/record.url?scp=18744389800&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18744389800&partnerID=8YFLogxK
U2 - 10.1007/s11912-005-0078-x
DO - 10.1007/s11912-005-0078-x
M3 - Article
C2 - 15847715
AN - SCOPUS:18744389800
SN - 1523-3790
VL - 7
SP - 228
EP - 233
JO - Current oncology reports
JF - Current oncology reports
IS - 3
ER -
